scholarly article | Q13442814 |
P50 | author | Neil E Kay | Q54295335 |
John G Gribben | Q61132226 | ||
William G Wierda | Q64026278 | ||
Michael J. Keating | Q66429598 | ||
John C. Byrd | Q66429603 | ||
Donna Neuberg | Q87319577 | ||
Michael R Grever | Q87630424 | ||
Kanti Rai | Q90696852 | ||
Laura Z Rassenti | Q114341050 | ||
P2093 | author name string | Thomas J Kipps | |
Feng He | |||
Jennifer R Brown | |||
Andrew W Greaves | |||
Sonia Jain | |||
P2860 | cites work | Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 |
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia | Q24675399 | ||
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. | Q33873343 | ||
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. | Q33956997 | ||
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment | Q34382878 | ||
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. | Q34521017 | ||
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens | Q35954301 | ||
CD38 as a prognostic marker in CLL. | Q36194534 | ||
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia | Q36285608 | ||
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia | Q36478480 | ||
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia | Q36914070 | ||
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century | Q40118546 | ||
CLL biology and prognosis | Q43536921 | ||
Clinical significance of CD38 expression in chronic lymphocytic leukemia | Q43775864 | ||
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. | Q44083652 | ||
CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. | Q44170509 | ||
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia | Q44189657 | ||
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. | Q44605532 | ||
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia | Q44730335 | ||
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia | Q44859885 | ||
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms | Q45247281 | ||
Regulation of protein tyrosine kinase activation by the T-cell antigen receptor zeta chain | Q46103645 | ||
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia | Q46112511 | ||
Molecular and genetic insights into T cell antigen receptor signal transduction | Q46279345 | ||
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia. | Q46472325 | ||
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia | Q47869313 | ||
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. | Q51119490 | ||
The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. | Q53661979 | ||
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. | Q53864608 | ||
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia | Q58041773 | ||
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor | Q58042045 | ||
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia | Q60358526 | ||
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential | Q61640131 | ||
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. | Q63347003 | ||
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile | Q73023141 | ||
Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia | Q73152569 | ||
When and how to treat chronic lymphocytic leukemia | Q73291688 | ||
CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia | Q73660995 | ||
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia | Q74064365 | ||
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia | Q77637148 | ||
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis | Q79569349 | ||
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia | Q80397477 | ||
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia | Q81324241 | ||
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia | Q82286248 | ||
The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia | Q82766574 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lymphocyte | Q715347 |
leukemia | Q29496 | ||
chronic lymphocytic leukemia | Q1088156 | ||
P304 | page(s) | 1923-1930 | |
P577 | publication date | 2008-06-24 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia | |
P478 | volume | 112 |
Q57279275 | A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia |
Q34917625 | A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. |
Q35220403 | Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia |
Q37517160 | Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia |
Q34549313 | Allogeneic transplantation for chronic lymphocytic leukemia |
Q31096565 | An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data |
Q33965688 | Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia |
Q50569242 | Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. |
Q58436696 | Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia |
Q28744086 | Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells |
Q36471596 | Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia |
Q37176527 | B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome |
Q37519737 | Bendamustine therapy in chronic lymphocytic leukemia |
Q33886052 | Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia |
Q36862781 | Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications |
Q37324992 | Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia |
Q35042003 | CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia |
Q44020427 | CD1d expression as a prognostic marker for chronic lymphocytic leukemia |
Q33517828 | CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data |
Q42770092 | CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia |
Q41488705 | Cellular origin and pathophysiology of chronic lymphocytic leukemia |
Q37615541 | Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia |
Q87869046 | Chronic lymphocytic leukaemia |
Q37771664 | Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells |
Q57034197 | Chronic lymphocytic leukemia treatment algorithm 2018 |
Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
Q26752467 | Chronic lymphocytic leukemia: a clinical review including Korean cohorts |
Q37734199 | Chronic lymphocytic leukemia: putting new treatment options into perspective |
Q33856248 | Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis |
Q36906625 | Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia |
Q47696260 | Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia |
Q64097680 | Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL |
Q39431594 | Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. |
Q50200689 | Cryptochrome-1 Gene Expression is a Reliable Prognostic Indicator in Egyptian Patients with Chronic Lymphocytic Leukemia: A Cohort Prospective Study |
Q35036721 | Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia |
Q34008593 | Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia |
Q42228343 | Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran |
Q33910990 | Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia |
Q37892409 | Detection methods of ZAP-70 in chronic lymphocytic leukemia |
Q35653850 | Developing Molecular Signatures for Chronic Lymphocytic Leukemia |
Q34418874 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia |
Q92158068 | Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations |
Q34349298 | Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia |
Q46333840 | Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. |
Q33832050 | ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver |
Q64062317 | Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia |
Q36462375 | Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia |
Q38239271 | Emerging roles for the FCRL family members in lymphocyte biology and disease |
Q92052916 | Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia |
Q36166026 | Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine |
Q50889970 | External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. |
Q37108980 | Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder |
Q38791698 | First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. |
Q40429099 | Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia |
Q34008866 | Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. |
Q37964914 | Front-line therapy for chronic lymphocytic leukemia |
Q36291109 | Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling |
Q33587644 | Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia |
Q38819164 | Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets |
Q33744997 | Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go |
Q91753087 | Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017 |
Q36886172 | High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. |
Q37427988 | High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia |
Q33813862 | High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival |
Q53192790 | Histone deacetylase in chronic lymphocytic leukemia. |
Q34137158 | How I treat CLL up front |
Q37537363 | How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia |
Q35814897 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia |
Q44563802 | IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group. |
Q38263806 | Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia |
Q37097096 | Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. |
Q33634389 | Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. |
Q28533669 | Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs |
Q35188629 | Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. |
Q36124370 | Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation |
Q37579289 | Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia |
Q64960368 | Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. |
Q42037602 | Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells |
Q38046045 | Inhibitors of B-cell receptor signaling for patients with B-cell malignancies |
Q37412319 | Karyotype-specific microRNA signature in chronic lymphocytic leukemia |
Q35143479 | LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia |
Q33859881 | Large-scale analysis of DNA methylation in chronic lymphocytic leukemia |
Q33796183 | Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium |
Q33774513 | Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia |
Q36942667 | Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia |
Q37187536 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia |
Q45806334 | Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. |
Q38755788 | Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies |
Q53108840 | Monoclonal B-cell lymphocytosis: definitions and natural history. |
Q36925185 | Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia |
Q33841975 | Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia |
Q35875424 | ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress |
Q88636732 | Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study |
Q40560266 | Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial |
Q35707206 | Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia |
Q38259446 | Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. |
Q83174110 | Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia |
Q37306304 | Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia |
Q33396594 | Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia |
Q34257190 | Predicting survival in chronic lymphocytic leukemia |
Q37879960 | Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study |
Q91708724 | Prognosis Factors in Chronic Lymphocytic Leukemia |
Q38345576 | Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma |
Q38691341 | Prognostic Factors for Chronic Lymphocytic Leukemia |
Q87856666 | Prognostic Factors in the Era of Targeted Therapies in CLL |
Q34166551 | Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation |
Q37801267 | Prognostic factors in chronic lymphocytic leukemia-what do we need to know? |
Q37738554 | Prognostic factors in low-grade non-Hodgkin lymphomas |
Q33758834 | Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells |
Q89637413 | Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group |
Q51151301 | Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. |
Q37188389 | Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia |
Q64244355 | Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia |
Q36097697 | Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia |
Q40185340 | Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. |
Q37004820 | Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia |
Q41768675 | Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers |
Q37387647 | Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia |
Q41915878 | Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells |
Q89879065 | Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia |
Q34348572 | Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review |
Q38189089 | Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia |
Q33822016 | SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course |
Q46467775 | Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria |
Q37195045 | Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results |
Q36194254 | Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans |
Q54704847 | Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. |
Q38062922 | Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype |
Q39085428 | State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia |
Q24642921 | Stem cell transplantation in chronic lymphocytic leukemia |
Q37948956 | Surface profiles for subclassification of chronic lymphocytic leukemia. |
Q87420514 | TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia |
Q49951221 | Targeting B cell receptor signalling in cancer: preclinical and clinical advances |
Q36762433 | Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. |
Q36165173 | The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells |
Q37130881 | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
Q38871618 | The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia |
Q34542102 | The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia |
Q28278125 | The molecular pathology of cancer |
Q40929264 | The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity |
Q35876861 | Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. |
Q36612587 | Treatment options for high-risk chronic lymphocytic leukaemia |
Q44683894 | Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia |
Q41812846 | Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia |
Q36603887 | Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia |
Q34016413 | Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia |
Q34750656 | White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia |
Q36774671 | Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China |
Search more.